Invivyd, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · New Haven, CT
IVVD chart
What traders are saying about $IVVD
Latest postsInvivyd, Inc. news
- Invivyd Spends $180K on Infectious Disease Lobbying
Legis1 ·
- IVVD Q2 2026 Earnings: Loss Widens Past Consensus, Yet Shares Move Higher - Gross Profit Margin
www.dars.gov.et ·
- Invivyd presents measles antibody candidate VMS063 data at IDWeek 2026
TipRanks ·
- Invivyd presents preclinical data on measles antibody candidate By Investing.com
Investing.com Nigeria ·
- Invivyd presents preclinical data on measles antibody candidate
Investing.com ·
- Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
Yahoo Finance ·
- More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.
Stock Titan ·
- Invivyd unveils VMS063, a promising monoclonal ...
Pluang ·
- Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
Yahoo Finance ·
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
marketbeat.com ·
- Invivyd’s Covid-directed mAb hits Phase III safety goals
clinicaltrialsarena.com ·
Invivyd, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $53.4M | $25.4M | $0 | – |
| Net income | -$52.5M | -$169.9M | -$198.6M | -$241.3M |
| Diluted EPS | $-0.30 | $-1.43 | $-1.81 | $-2.23 |
| Total assets (year end) | $276.9M | $129.5M | $229.2M | $383.2M |
| Cash and equivalents (year end) | $226.7M | $69.3M | $200.6M | $92.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Invivyd, Inc.
- Ticker
- IVVD (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- New Haven, CT
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1832038
- Former names
- Adagio Therapeutics, Inc.
Frequently asked questions
What exchange is Invivyd, Inc. listed on?
Invivyd, Inc. trades on the Nasdaq under the ticker symbol IVVD.
What industry is Invivyd, Inc. in?
Invivyd, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Invivyd, Inc. headquartered?
Invivyd, Inc.'s business address on file with the SEC is in New Haven, CT.
When does Invivyd, Inc.'s fiscal year end?
Invivyd, Inc.'s fiscal year ends on December 31.
How much revenue did Invivyd, Inc. report?
Invivyd, Inc. reported $53.4M in revenue for calendar year 2025, according to its SEC filings.